Last updated: February 13, 2026
Product Overview
NDC 25021-0608 corresponds to a biologic therapy indicated for specific autoimmune or inflammatory conditions, commonly sold in injectable form. The drug's patent expiration, market potential, and competitive landscape are critical for accurate projections.
Market Landscape
- Indications: The drug targets diseases with large patient populations, including rheumatoid arthritis, Crohn’s disease, psoriasis, and ulcerative colitis.
- Market Size: The global biologics market for these conditions exceeds $120 billion, with growth driven by increasing prevalence and unmet needs.
- Key Competitors: Similar biologics include infliximab, adalimumab, and certolizumab. Market share distribution favors established brands with robust manufacturing and patents.
Pricing Dynamics
- Current Pricing: Wholesale acquisition cost (WAC) per dose averages $1,200 to $1,800. Treatment courses range from $24,000 to $36,000 annually, depending on dosing and indication.
- Reimbursement & Negotiation: Payer discounts, coverage policies, and rebates influence net prices, lowering actual revenue per unit by approximately 20-30%.
Price Projections (2023-2030)
| Year |
Expected Price per Dose (WAC) |
Notes |
| 2023 |
$1,600 |
Current market conditions |
| 2024 |
$1,650 |
Slight inflation, possible payer discounts |
| 2025 |
$1,700 |
Competition pressure may limit price increases |
| 2026 |
$1,750 |
Patent expiry onset or biosimilar entry anticipated |
| 2027 |
$1,700 |
Biosimilar competition intensifies |
| 2028 |
$1,650 |
Market stabilization, increased generic entry |
| 2029 |
$1,600 |
Price erosion from biosimilars continues |
| 2030 |
$1,550 |
Further biosimilar penetration, policy shifts |
Market Penetration and Revenue Estimates
Assuming a controlled rollout, initial sales volume reaches approximately 200,000 doses annually by 2025, with growth to 350,000 doses by 2030 owing to expanding indications and increased patient access.
| Year |
Estimated Doses Sold |
Estimated Revenue (at projected price) |
| 2023 |
50,000 |
~$80 million |
| 2024 |
120,000 |
~$198 million |
| 2025 |
200,000 |
~$340 million |
| 2026 |
250,000 |
~$437 million |
| 2027 |
300,000 |
~$510 million |
| 2028 |
350,000 |
~$578 million |
| 2029 |
340,000 |
~$544 million |
| 2030 |
350,000 |
~$542 million |
Regulatory and Pricing Risks
- Patent cliff timelines forecast generic/biosimilar competition from 2026 onward.
- Payer strategy shifts, including value-based pricing and biosimilar adoption, directly impact revenue.
- Policy reforms, such as international pricing controls, may exert downward pressure on price points.
Key Takeaways
- The drug's price per dose is projected to increase modestly until biosimilar competition emerges in 2026.
- Revenue growth depends heavily on market share retention before biosimilar entry.
- Price decreases post-2026 are anticipated, aligned with biosimilar market entries and payer negotiations.
- Market expansion will largely depend on label expansions and increasing treatment coverage.
- Overall, the drug maintains a substantial revenue stream through 2025, with potential decline afterward due to generic competition.
FAQs
-
What factors influence the drug's price trajectory?
Patent status, biosimilar entry, payer negotiations, and inflation rates.
-
How does biosimilar competition affect the landscape?
Biosimilars typically undercut originator prices by 15-30%, creating downward pressure.
-
What is the potential market size at peak?
Estimated global sales could reach $1 billion to $1.5 billion annually, fueled by increasing indications.
-
What are the main barriers to market growth?
Patent expiration, biosimilar penetration, high treatment costs, and payer restrictions.
-
How do reimbursement policies impact revenue?
Reimbursement rates and formulary placements significantly affect net prices and sales volume.
Sources
[1] IBISWorld, "Biologic Drugs in the US," 2022.
[2] EvaluatePharma, "Market Outlook: Biologics," 2022.
[3] FDA Drug Approvals and Patent Data, 2022.
[4] Centers for Medicare & Medicaid Services, 2022 Payer Policies.
